DISCLOSURE INDEX - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

Practical Recommendations in Immuno and Molecular Oncology (PRIMO)
February 5-8, 2025

Honolulu, HI

DISCLOSURE INDEX

The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold, disclosure must be made regardless of whether the person views the financial relationships
as relevant to the education. The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.

As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all financial relationships with any ineligible companiesto the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.

The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

Speakers/Moderators – Reported Relevant Financial Disclosure(s) 

Jared D. Acoba, MD

Grant/Research Support: GSK

 

Sanjiv S. Agarwala, MD, FASCO

Has no relevant financial relationships

 

Daniel H. Ahn, DO, MS

Grant/Research Support: AstraZeneca

Consultant: Bayer

Stock Shareholders: Natera

 

Shannon Baxter, PhD

Has no relevant financial relationships

 

Susana Campos, MD, MPH

Consultant: Esai, GlaxoSmithKline, Merck, Pfizer, Immunogen

Michael E. Carney, MD, FACOG

Has no relevant financial relationships

Darlena Chadwick, MBA, MSN, FACHE

Has no relevant financial relationships

 

Cecilia Choi, MD

Has no relevant financial relationships

 

Amy L. Cummings, MD, PhD

Consultant: AstraZeneca, Bristol Myers Squibb, Oncohost, Tempus

 

Don S. Dizon, MD, FACP, FASCO

Grant/Research Support: Bristol Myers Squibb

Consultant: Puma,

Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change

Management: Clovis

Stock Shareholders: Midi, Doximity

 

Jami Fukui, MD

Has no relevant financial relationships

 

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE

Grant/Research Support: BMS, Pharmacosmos

 

Nitin Jain, MD

Grant/Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead, Mingsight Pharmaceuticals, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave Pharmaceutical Inc., Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology

Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight Pharmaceuticals, Autolus, Novalgen

 

Robert Kim, MD

Has no relevant financial relationships

 

Kami J. Maddocks, MD

Consultant: Abbvie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Genetech, Genmab, Incyte, Janssen, Kite, MorphoSys

 

Midhun Malla, MD, MS

Consultant: Exegesis, Ipsen, Natera

 

Tom Martin, MD

Grant/Research Support: Sanofi, Janssen, Amgen, BMS

Consultant: GSK, Roche/Pfizer

 

Shane Y. Morita, MD, MBA, PhD, FACS, FSSO

Has no relevant financial relationships

 

Misako Nagasaka, MD, PhD

Grant/Research Support: AstraZeneca, Daiichi Sankyo, Lilly, Janssen, BMS/Mirati, AnHeart/Nuvation, Nuvalent, JintsBIO, D3Bio, Boehringer Ingelheim, Merus

Consultant: Caris Life Sciences

Speakers’ Bureau: Janssen, Pfizer, Takeda, Blueprint Medicine

Stock Shareholders: MBrace Therapeutics

 

Jorge J. Nieva, MD

Grant/Research Support: Genentech, Merck

Consultant: Aadi Biosciences, Affyimmune, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics, Genentech, Kalivir Mindmed, Naveris, Sanofi

Stock Shareholders: Cansera, Epic Sciences, Indee Bio, Quantgene, Amgen, Johnson & Johnson, Novartis

 

Joyce O’Shaughnessy, MD

Has no relevant financial relationships

 

Alexander B. Olawaiye, MD

Has no relevant financial relationships

 

Chandler H. Park, MD, MSc, FACP

Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Gilead Sciences, Janssen, Merck, Pfizer/Roche

Consultant: Aveo, AstraZeneca, Bristol-Myers Squibb, Caris, Exelixis, Eisai, Gilead Sciences, Janssen, Pfizer, Merck

Speakers’ Bureau: Eisai, Gilead Sciences, Pfizer, AstraZeneca, Merck, Janssen

 

Mark Pegram, MD

Consultant: Roche/Genentech, Stemline, AstraZeneca/Daiichi Sankyo

 

Luis E. Raez, MD, FACP, FASCO

Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant Health, Genentech, Onc4, Anheart, Arcus Biosciences

Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis

 

Merrick I. Ross, MD

Consultant: Merck – US Global Advisory Board Member

 

Hope S. Rugo, MD, FASCO

Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambryx

Consultant: Chugai, Puma, Sanofi, Napo, Mylan

 

Stuart Tsuji, MD, PhD

Has no relevant financial relationships

 

Naoto T. Ueno, MD, PhD, FACP

Grant/Research Support: AnHeart Therapeutics Inc., Eisai Co., Ltd., Gilead Sciences, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., Merck & Co., Oncolys BioPharma Inc., OBI Pharma Inc., ChemDiv, Inc., Tolero Pharmaceuticals, Inc., and VITRAC Therapeutics, LLC All have ended

Consultant: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG (ended), Bristol Myers Squibb Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly, Genentech, Inc. (ended), Genomic Health, Inc. (ended), Gilead Sciences, Inc.(ended), Lavender Health (ended), OncoCyte Corporation (ended), Pear Bio, Peptilogics, Inc.(ended), Pfizer Inc.(ended), Phoenix Molecular Designs, Preferred Medicine (ended), Carisma Therapeutics Inc.(ended), Sysmex Corporation (ended), Takeda Pharmaceutical Company Limited (Japan)(ended), and Unitech Medical, Inc.(ended)

Speakers’ Bureau: AstraZeneca Pharmaceuticals LP (ended), Chugai Roche, Inc.(ended), Daiichi Sankyo

Co., Ltd.(ended), Kyowa Kirin Co., Ltd.(ended), Pfizer Inc.(ended), Eli Lilly (ended).

Stock Shareholders: Pear Bio, Phoenix Molecular Designs

 

Vicente Valero, MD, FACP

Consultant: Novartis, AstraZeneca, Roche

 

Julie M. Vose, MD, MBA

Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo

Consultant: GenMab/Abbvie

 

Eunice S. Wang, MD

Consultant: Abbvie, CTI Biopharma, BMS, Blueprint, Daiichi Sankyo, Gilead, GSK, Immunogen, J&J, Kite,
Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Sumitomo, Syndax, Takeda

Speakers’ Bureau: Astellas, Pfizer, Dava, Daiichi Sankyo

Other: Data Safety Monitoring Committee: Abbvie, Gilead

 

Yousef Zakharia, MD

Consultant: Advisory Board: BMS, EMD Serono, Exelixis, Eisai, Gilead, Janssen, Pfizer, Seagen

 

The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold, disclosure must be made regardless of whether the person views the financial relationships as relevant to the education.  The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.

As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.

The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

Speakers/Moderators – Relevant Financial Disclosure(s)

Jared D. Acoba, MD
Grant/Research Support:
GSK

 

Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships

 

Daniel H. Ahn, DO, MS

Grant/Research Support: AstraZeneca

Consultant: Bayer

Stock Shareholders: Natera

 

Shannon Baxter, PhD

Has no relevant financial relationships

 

Susana Campos, MD, MPH

Consultant: Esai, GlaxoSmithKline, Merck, Pfizer, Immunogen

 

Michael E. Carney, MD, FACOG

Has no relevant financial relationships

 

Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships

 

Cecilia Choi, MD
Has no relevant financial relationships

 

Amy L. Cummings, MD, PhD
Consultant:
AstraZeneca, Bristol Myers Squibb, Oncohost, Tempus

 

Don S. Dizon, MD, FACP, FASCO
Grant/Research Support:
Bristol Myers Squibb
Consultant:
Puma,
Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis
Stock Shareholders:
Midi, Doximity

 

Jami Fukui, MD
Has no relevant financial relationships

 

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support:
BMS, Pharmacosmos

 

Nitin Jain, MD
Grant/Research Support:
Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC
Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite/Gilead,
Mingsight Pharmaceuticals, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave
Pharmaceutical Inc., Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology

Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies,
Kite/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight
Pharmaceuticals, Autolus, Novalgen

 

Robert Kim, MD
Has no relevant financial relationships

 

Kami J. Maddocks, MD

Consultant: Abbvie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company,
Genetech, Genmab, Incyte, Janssen, Kite, MorphoSys

 

Midhun Malla, MD, MS

Consultant: Exegesis, Ipsen, Natera

 

Tom Martin, MD

Grant/Research Support: Sanofi, Janssen, Amgen, BMS

Consultant: GSK, Roche/Pfizer

 

Shane Y. Morita, MD, MBA, PhD, FACS, FSSO

Has no relevant financial relationships

 

Misako Nagasaka, MD, PhD
Grant/Research Support:
AstraZeneca, Daiichi Sankyo, Lilly, Janssen, BMS/Mirati,
AnHeart/Nuvation, Nuvalent, JintsBIO, D3Bio, Boehringer Ingelheim, Merus

Consultant: Caris Life Sciences

Speakers’ Bureau: Janssen, Pfizer, Takeda, Blueprint Medicine

Stock Shareholders: MBrace Therapeutics

 

Jorge J. Nieva, MD

Grant/Research Support: Genentech, Merck

Consultant: Aadi Biosciences, Affyimmune, ANP Technologies, Astra Zeneca, BioAtla, G1 Therapeutics,
Genentech, Kalivir Mindmed, Naveris, Sanofi

Stock Shareholders: Cansera, Epic Sciences, Indee Bio, Quantgene, Amgen, Johnson & Johnson, Novartis

 

Joyce O’Shaughnessy, MD

Has no relevant financial relationships

 

Alexander B. Olawaiye, MD

Has no relevant financial relationships

 

Chandler H. Park, MD, MSc, FACP

Grant/Research Support: AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Gilead Sciences, Janssen,
Merck, Pfizer/Roche

Consultant: Aveo, AstraZeneca, Bristol-Myers Squibb, Caris, Exelixis, Eisai, Gilead Sciences, Janssen,
Pfizer, Merck

Speakers’ Bureau: Eisai, Gilead Sciences, Pfizer, AstraZeneca, Merck, Janssen

 

Mark Pegram, MD

Consultant: Roche/Genentech, Stemline, AstraZeneca/Daiichi Sankyo

 

Luis E. Raez, MD, FACP, FASCO
Grant/Research Support:
AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant
Health, Genentech, Onc4, Anheart, Arcus Biosciences

Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis

 

Merrick I. Ross, MD

Consultant: Merck – US Global Advisory Board Member

 

Hope S. Rugo, MD, FASCO
Grant/Research Support:
AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc.,
Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline
Therapeutics, OBI Pharma, Ambryx

Consultant: Chugai, Puma, Sanofi, Napo, Mylan

 

Stuart Tsuji, MD, PhD

Has no relevant financial relationships

 

Naoto T. Ueno, MD, PhD, FACP
Grant/Research Support:
AnHeart Therapeutics Inc., Eisai Co., Ltd., Gilead Sciences, Inc., Phoenix
Molecular Designs, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., Merck & Co., Oncolys BioPharma Inc.,
OBI Pharma Inc., ChemDiv, Inc., Tolero Pharmaceuticals, Inc., and VITRAC Therapeutics, LLC All have
ended

Consultant: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG (ended), Bristol Myers Squibb
Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly,
Genentech, Inc. (ended), Genomic Health, Inc. (ended), Gilead Sciences, Inc.(ended), Lavender Health
(ended), OncoCyte Corporation (ended), Pear Bio, Peptilogics, Inc.(ended), Pfizer Inc.(ended),
Phoenix

Molecular Designs, Preferred Medicine (ended), Carisma Therapeutics Inc.(ended), Sysmex Corporation
(ended), Takeda Pharmaceutical Company Limited (Japan)(ended), and Unitech Medical, Inc.(ended)

Speakers’ Bureau: AstraZeneca Pharmaceuticals LP (ended), Chugai Roche, Inc.(ended), Daiichi Sankyo
Co., Ltd.(ended), Kyowa Kirin Co., Ltd.(ended), Pfizer Inc.(ended), Eli Lilly (ended).
Stock Shareholders: Pear Bio, Phoenix Molecular Designs

 

Vicente Valero, MD, FACP
Consultant:
Novartis, AstraZeneca, Roche

 

Julie M. Vose, MD, MBA
Grant/Research Support:
GenMab/Abbvie, Ipsen, Loxo
Consultant:
GenMab/Abbvie

 

Yousef Zakharia, MD

Consultant: Advisory Board: BMS, EMD Serono, Exelixis, Eisai, Gilead, Janssen, Pfizer, Seagen

 

Planning Committee – Reported Relevant Financial Disclosure(s) 

 

Sanjiv S. Agarwala, MD, FASCO

Has no relevant financial relationships

 

Darlena Chadwick, MBA, MSN, FACHE

Has no relevant financial relationships

 

Don S. Dizon, MD, FACP, FASCO

Grant/Research Support: Bristol Myers Squibb

Consultant: Puma,

Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change

Management: Clovis

Stock Shareholders: Midi, Doximity

 

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE

Grant/Research Support: BMS, Pharmacosmos

 

Shane Y. Morita, MD, MBA, PhD, FACS, FSSO

Has no relevant financial relationships

 

Luis E. Raez, MD, FACP, FASCO

Grant/Research Support: AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant Health, Genentech, Onc4, Anheart, Arcus Biosciences

Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis

 

Hope S. Rugo, MD, FASCO

Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambryx

Consultant: Chugai, Puma, Sanofi, Napo, Mylan

 

Amy Schippers, PA-C

Has no relevant financial relationships

 

Teri Valls, CMP, CMM

Has no relevant financial relationships

 

Julie M. Vose, MD, MBA

Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo

Consultant: GenMab/Abbvie

 

CME Reviewers – Reported Relevant Financial Disclosure(s) 

Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships


Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships


Lynne Davidson
Has no relevant financial relationships


Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support: BMS, Pharmacosmos

Amy Schippers, PA-C
Has no relevant financial relationships


Teri Valls, CMP, CMM
Has no relevant financial relationships

 

All of the relevant financial relationships listed for these individuals have been mitigated.

 

SPEAKERS WILL DIRECTLY DISCLOSETHE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE

Planning Committee – Relevant Financial Disclosure(s) 

Sanjiv S. Agarwala, MD, FASCO

Has no relevant financial relationships

 

Darlena Chadwick, MBA, MSN, FACHE

Has no relevant financial relationships

 

Don S. Dizon, MD, FACP, FASCO
Grant/Research Support:
Bristol Myers Squibb

Consultant: Puma,

Other: Data Safety Monitoring Board: Astra Zeneca, Data Safety Monitoring Board & Change
Management: Clovis

Stock Shareholders: Midi, Doximity

 

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE

Grant/Research Support: BMS, Pharmacosmos

 

Shane Y. Morita, MD, MBA, PhD, FACS, FSSO

Has no relevant financial relationships

 

Luis E. Raez, MD, FACP, FASCO
Grant/Research Support:
AstraZeneca, Pfizer, Velos, Merck, TG Therapeutics, BMS, Natera, Guardant
Health, Genentech, Onc4, Anheart, Arcus Biosciences

Consultant: Bayer, AstraZeneca, Pfizer, Merck, Novartis

 

Hope S. Rugo, MD, FASCO

Grant/Research Support: AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc.,
Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline
Therapeutics, OBI Pharma, Ambryx

Consultant: Chugai, Puma, Sanofi, Napo, Mylan

 

Amy Schippers, PA-C

Has no relevant financial relationships

 

Teri Valls, CMP, CMM

Has no relevant financial relationships

 

Julie M. Vose, MD, MBA

Grant/Research Support: GenMab/Abbvie, Ipsen, Loxo
Consultant: GenMab/Abbvie

 

CME Reviewers – Relevant Financial Disclosure(s)

Sanjiv S. Agarwala, MD, FASCO
Has no relevant financial relationships


Darlena Chadwick, MBA, MSN, FACHE
Has no relevant financial relationships


Lynne Davidson
Has no relevant financial relationships


Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Grant/Research Support:
BMS, Pharmacosmos

 

Amy Schippers, PA-C
Has no relevant financial relationships


Teri Valls, CMP, CMM
Has no relevant financial relationships

 

All of the relevant financial relationships listed for these individuals have been mitigated.

 

SPEAKERS WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF

LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO

KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE.